Faculty profile

Anna Tinker

ResearcherObstetrics and GynecologyUniversity of British Columbia

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a University of British Columbia directory, so their courses and email address may be missing. Find their university profile.

Anna Tinker

Researcher

Obstetrics and Gynecology

Health Sciences

University of British Columbia

Vancouver, British Columbia, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
7 publications in the last five years, latest in 2026.
Principal investigator on 3 research grants (3 CIHR), most recently in 2022.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

Citations

h-index

Collaborators

Grants

Publications by year

Counts cover the works listed on the university profile; citation counts come from Dimensions.

Profiles and links

Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Endometrial Cancer Biomarkers Digital Health Early Detection Health Equity Predictive Modelling Risk Prediction Self-Tracking

Latest papers

Consensus Statement from the Society of Gynecologic Oncology of Canada on Folate Receptor α Testing in Ovarian Cancer.
Current oncology (Toronto, Ont.) · 2026
Lymph node involvement, surgery and adjuvant treatment in primary Endometrioid Ovarian carcinoma PAtients with eaRly-stage Disease (LEOPARD) - a multinational team initiative.
Gynecologic oncology · 2026
Collaborative team-based care implementation in ambulatory gynecological and lung cancer clinics.
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners · 2025

All 22 publications

Latest funding

Digital self-tracking and self-testing for early detection of endometrial cancer
CIHR · 2022 · Principal investigator
$879,750
Deconvoluting Prognostic and Targetable Features of Endometrioid Ovarian Carcinomas of No Specific Molecular Profile
CIHR · 2022 · Co-investigator
$646,424
Digital self-tracking for early detection and prevention of endometrial cancer during reproductive aging
CIHR · 2021 · Principal investigator
$100,000

All 4 grants and awards

22 publications.

Consensus Statement from the Society of Gynecologic Oncology of Canada on Folate Receptor α Testing in Ovarian Cancer.

Ma K, Tessier-Cloutier B, Altman AD, Carey MS, Ethier JL, Lau S, Lee CH, Hopkins L, Kieser K, Kumar A, Leung SOA, Nguyen JMV, MacKay H, McGee J, Salman L, Salvador S, Sluce C, Tatar L, Tone AA, Tinker A, Tremblay E, Veneziani AC, Vicus D, Welch S, Windsor Harker S, Brodeur MN

Current oncology (Toronto, Ont.)2026

DOI: 10.3390/curroncol33060330 PMID: 42346230

Lymph node involvement, surgery and adjuvant treatment in primary Endometrioid Ovarian carcinoma PAtients with eaRly-stage Disease (LEOPARD) - a multinational team initiative.

Grube M, Ribeiro de Souza B, Neilson A, Tinker A, Staebler A, Kuzma T, Nelson GS, de Kroon C, Bosse T, Kroep JR, Teo-Fortin LA, Bachvarov D, Brummel K, de Bruyn M, Nijman H, Andres S, Schochter F, Fink A, Moubarak M, Heitz F, Harter P, Bartl T, Grimm C, Hofstetter G, Sideris M, Manchanda R, Heublein S, Fischer-Straub A, Kommoss FKF, Kulkarni A, Vanderhyden B, Knoll K, Zeimet A, Wimberger P, Link T, Jaeger A, Schmalfeldt B, Lampe B, Yasmeen A, Phouthavongsy L, Vollert HW, Lycke M, Mateoiu CC, Irving J, Watson P, Nachtigal M, de Ladurantaye M, van de Laar E, Plante M, Kommoss F, Talhouk A, Koebel M, Anglesio MS, Kommoss S

Gynecologic oncology2026

DOI: 10.1016/j.ygyno.2026.04.008 PMID: 42090883

Collaborative team-based care implementation in ambulatory gynecological and lung cancer clinics.

Abadi S, Pool A, Tinker A, Wang Y, Crameri A, Jang D

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners2025

DOI: 10.1177/10781552251351324 PMID: 40551673

Durvalumab and tremelimumab in patients with advanced rare cancer: a multi-centre, non-blinded, open-label phase II basket trial

Gupta AA, Tinker A, Jonker D, Jamal R, Hirte H, Winquist EW, Chu Q, Kollmannsberger C, Wong R, Alcindor T

EClinicalMedicine20255 citations

DOI: 10.1016/j.eclinm.2024.102991

How long is long enough? An international survey exploring practice variations on the recommended duration of maintenance therapy with PARP inhibitors in patients with platinum sensitive recurrent ovarian cancer and long-term outcomes.

Haggstrom L, Lee YC, Scott C, Harter P, Woelber L, Ledermann J, Gourley C, McNeish IA, Amant F, Ray-Coquard I, Leary A, Oza AM, Tinker A, González Martin A, Cecere SC, Pignata S, Colombo N, Yoshida H, Marth C, Rosengarten O, Moore KN, Gómez-García EM, Tan D, Friedlander ML

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society2024

DOI: 10.1136/ijgc-2024-005976 PMID: 39438068

Evaluating the childcare needs of cancer patients undergoing radiation therapy.

Li ZHJ, MacDonald K, Preston K, Giuliani M, Leung B, Melosky B, Simmons C, Hamilton S, Tinker A, Ingledew PA

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2023

DOI: 10.1007/s00520-023-07923-z PMID: 37439947

Impact of the adjuvant management and risk factors on survival in FIGO stage 3 endometrial cancer patients.

Tong N, Kumar A, Gelowitz G, Tinker A, Holloway C, Ko J

Frontiers in oncology2023

DOI: 10.3389/fonc.2023.1035511 PMID: 37091159

From biobank and data silos into a data commons: convergence to support translational medicine.

Asiimwe R, Lam S, Leung S, Wang S, Wan R, Tinker A, McAlpine JN, Woo MMM, Huntsman DG, Talhouk A

Journal of translational medicine2021

DOI: 10.1186/s12967-021-03147-z PMID: 34863191

Adjuvant Treatment of Early Ovarian Clear Cell Carcinoma: A Population-Based Study of Whole Abdominal Versus Pelvic Nodal Radiotherapy.

Roy S, Hoskins P, Tinker A, Brar H, Bowering G, Bahl G

Journal of the National Comprehensive Cancer Network : JNCCN2020

DOI: 10.6004/jnccn.2020.7609 PMID: 32971514

Pan-cancer analysis of advanced patient tumors reveals interactions between therapy and genomic landscapes.

Pleasance E, Titmuss E, Williamson L, Kwan H, Culibrk L, Zhao EY, Dixon K, Fan K, Bowlby R, Jones MR, Shen Y, Grewal JK, Ashkani J, Wee K, Grisdale CJ, Thibodeau ML, Bozoky Z, Pearson H, Majounie E, Vira T, Shenwai R, Mungall KL, Chuah E, Davies A, Warren M, Reisle C, Bonakdar M, Taylor GA, Csizmok V, Chan SK, Zong Z, Bilobram S, Muhammadzadeh A, D'Souza D, Corbett RD, MacMillan D, Carreira M, Choo C, Bleile D, Sadeghi S, Zhang W, Wong T, Cheng D, Brown SD, Holt RA, Moore RA, Mungall AJ, Zhao Y, Nelson J, Fok A, Ma Y, Lee MKC, Lavoie JM, Mendis S, Karasinska JM, Deol B, Fisic A, Schaeffer DF, Yip S, Schrader K, Regier DA, Weymann D, Chia S, Gelmon K, Tinker A, Sun S, Lim H, Renouf DJ, Laskin J, Jones SJM, Marra MA

Nature cancer2020

DOI: 10.1038/s43018-020-0050-6 PMID: 35121966

Something wrong or missing on this profile? Suggest a correction

Anna Tinker

Research

Latest papers

Latest funding

Consensus Statement from the Society of Gynecologic Oncology of Canada on Folate Receptor &#x3b1; Testing in Ovarian Cancer.

Lymph node involvement, surgery and adjuvant treatment in primary Endometrioid Ovarian carcinoma PAtients with eaRly-stage Disease (LEOPARD) - a multinational team initiative.

Collaborative team-based care implementation in ambulatory gynecological and lung cancer clinics.

Durvalumab and tremelimumab in patients with advanced rare cancer: a multi-centre, non-blinded, open-label phase II basket trial

How long is long enough? An international survey exploring practice variations on the recommended duration of maintenance therapy with PARP inhibitors in patients with platinum sensitive recurrent ovarian cancer and long-term outcomes.

Evaluating the childcare needs of cancer patients undergoing radiation therapy.

Impact of the adjuvant management and risk factors on survival in FIGO stage 3 endometrial cancer patients.

From biobank and data silos into a data commons: convergence to support translational medicine.

Adjuvant Treatment of Early Ovarian Clear Cell Carcinoma: A Population-Based Study of Whole Abdominal Versus Pelvic Nodal Radiotherapy.

Pan-cancer analysis of advanced patient tumors reveals interactions between therapy and genomic landscapes.

Digital self-tracking and self-testing for early detection of endometrial cancer

Deconvoluting Prognostic and Targetable Features of Endometrioid Ovarian Carcinomas of No Specific Molecular Profile

Digital self-tracking for early detection and prevention of endometrial cancer during reproductive aging

Personalizing Prevention Strategies in Endometrial Cancer

Frequent collaborators

Stephen Welch

Aline Talhouk

Kasmintan Schrader

Sebastien Hotte

Ying Wang

Lesley Seymour

Basile Tessier-Cloutier

Stephanie Lheureux

Meredith Giuliani

Derek Jonker

John Hilton

Lisa Wang

Jacob McGee

David Huntsman

Samuel Aparicio

Barbara Vanderhyden

Jessica Mcalpine

Janet Dancey

Steven Jones

Alan So

Peter Watson

Wei Zhang

Holger Hirte

Aly Karsan

Consensus Statement from the Society of Gynecologic Oncology of Canada on Folate Receptor α Testing in Ovarian Cancer.